Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS (2015) Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 41:120–127
PubMedPubMedCentralCrossRefBapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M (2016) Cone beam computed tomography (CBCT) in the field of interventional oncology of the liver. Cardiovasc Intervent Radiol 39:8–20
PubMedCrossRefBernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, Divgi C, Zanzonico P, Stare J, Buscombe J, Minh CT, Saw MM, Chen S, Ogbac R, Padhy AK (2007) Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys 69:1448–1455
PubMedCrossRefBouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N (2018) Transarterial radioembolization (TARE) agents beyond (90)Y-microspheres. Biomed Res Int 2018:1435302
PubMedPubMedCentralCrossRefBraat MN, van Erpecum KJ, Zonnenberg BA, van den Bosch MA, Lam MG (2017) Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol 29:144–152
PubMedCrossRefChow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC, Group Asia-Pacific Hepatocellular Carcinoma Trials (2018) SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36:1913–1921
PubMedCrossRefCosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F, Oncology Italian Society of Locoregional Therapies in (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331
PubMedPubMedCentralCrossRefCutsem E Van, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27:1386–1422
Dendy MS, Ludwig JM, Kim HS (2017) Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget 8:37912–37922
PubMedPubMedCentralCrossRefDeutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten, V. Netzwerk Neuroendokrine Tumoren e, V. Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e, und Arbeitsgemeinschaft Internistische Onkologie der Deutschen Krebsgesellschaft e, V. Deutsche Gesellschaft für Hamatologie und Medizinische Onkologie e.V, V. Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e, Chirurgie Deutsche Gesellschaft für, Verfahren Deutsche Gesellschaft für Endoskopie und Bildgebende, V. Deutsche Gesellschaft für Nuklearmedizin e, Medizin Deutsche Gesellschaft für, Innere, Endokrinologie Deutsche Gesellschaft fur, V. Deutsche Gesellschaft für Palliativmedizin e, V. Deutsche Röntgengesellschaft e, V. Bundesverband Deutscher Pathologen Deutsche Gesellschaft für Pathologie e, Radiologie Deutsche Gesellschaft für interventionelle, Authors, and Collaborators (2018) S2k-Leitlinie Neuroendokrine Tumore – AWMF-Reg. 021-27. Z Gastroenterol 56:583–681
European Association for the Study of the Liver. Electronic address, easloffice easloffice eu, and European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol
Fowler KJ, Maughan NM, Laforest R, Saad NE, Sharma A, Olsen J, Speirs CK, Parikh PJ (2016) PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol 39:855–864
PubMedCrossRefGaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16:1587–1596
PubMedCrossRefGarin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Poree P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc’h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E (2013) Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging 40:1057–1068
PubMedPubMedCentralCrossRefGil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, Benito A, Dominguez I, D’Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57:1078–1087
PubMedCrossRefHazel G Van, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B (2004). Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer, J Surg Oncol, 88:78–85
Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694
PubMedCrossRefHilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52:1741–1749
PubMedCrossRefHoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, Reiser MF, Kolligs FT (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35:105–116
PubMedCrossRefIbrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A 3rd, Omary RA, Salem R (2008) Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113:2119–2128
PubMedCrossRefJia Z, Wang W (2018) Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol 100:23–29
PubMedCrossRefJoo I, Kim HC, Kim GM, Paeng JC (2018) Imaging evaluation following (90)Y radioembolization of liver tumors: what radiologists should know. Korean J Radiol 19:209–222
PubMedPubMedCentralCrossRefKallini JR, Gabr A, Salem R, Lewandowski RJ (2016) Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther 33:699–714
PubMedPubMedCentralCrossRefLevillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Cheenu Kappadath S, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, de la Cuesta AM, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der Veen BJ, Flamen P (2021) International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 48:1570–1584
Lewandowski RJ, Salem R (2006) Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 23:64–72
PubMedPubMedCentralCrossRefLewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, Geschwind JF, Murthy R, Rilling W, Liu D, Bester L, Bilbao JI, Kennedy AS, Omary RA, Salem R (2007) Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30:571–592
PubMedCrossRefLewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9:1920–1928
PubMedCrossRefLewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, Kulik L, Ganger D, Desai K, Thornburg B, Mouli S, Hickey R, Caicedo JC, Abecassis M, Riaz A, Salem R (2018) Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 287:1050–1058
PubMedCrossRefMarelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK (2009) Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 50:871–877
PubMedCrossRefMcDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, Sands M, Narayanan Menon KV, Aucejo FN, Estfan B, Pillai AK, Kalva SP, McLennan G (2017) Single-center comparison of overall survival and toxicities in patients with infiltrative hepatocellular carcinoma treated with Yttrium-90 radioembolization or drug-eluting embolic transarterial chemoembolization. J Vasc Interv Radiol 28:1371–1377
PubMedCrossRefMemon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R (2011) Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol 21:294–302
PubMedPubMedCentralCrossRefPowerski MJ, Scheurig-Munkler C, Banzer J, Schnapauff D, Hamm B, Gebauer B (2012) Clinical practice in radioembolization of hepatic malignancies: a survey among interventional centers in Europe. Eur J Radiol 81:e804–e811
PubMedCrossRefRayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, Boucher E, Boudjema K (2015) Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 22:3102–3108
PubMedCrossRefReinders MTM, Mees E, Powerski MJ, Bruijnen RCG, van den Bosch M, Lam M, Smits MLJ (2018) Radioembolisation in Europe: a survey amongst CIRSE members. Cardiovasc Intervent Radiol 41:1579–1589
PubMedPubMedCentralCrossRefRicke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schutte K, Verslype C, Walecki J, Malfertheiner P, Soramic Study Group (2015) Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int 35:620–626
PubMedCrossRefRicke J, Sangro B, Amthauer H, Bargellini I, Bartenstein P, De Toni E, Gasbarrini A, Klümpen HJ, Peck-Radosavljevic M, Popovic P, Rosmorduc O, Schott E, Van Buskirk M, Malfertheiner P (2018) The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial palliative cohort. J Hepatol 68:S102
CrossRefSalem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639
PubMedCrossRefSalem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497.e2–507.e2
CrossRefSalem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11:1358.e1–1365.e1
Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ (2018) Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 68:1429–1440
PubMedCrossRefSavic LJ, Chapiro J, Geschwind J-FH (2017) Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatob Surg Nutr 6:7–21
CrossRefSchernthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF (2016) Improved visibility of metastatic disease in the liver during intra-arterial therapy using delayed arterial phase cone-beam CT. Cardiovasc Intervent Radiol 39:1429–1437
PubMedPubMedCentralCrossRefSchmiegel W, Buchberger B, Follmann M, Graeven U, Heinemann V, Langer T, Nothacker M, Porschen R, Rodel C, Rosch T, Schmitt W, Wesselmann S, Pox C (2017) S3-Leitlinie – Kolorektales Karzinom. Z Gastroenterol 55:1344–1498
PubMedCrossRefSchobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ (2019) Quantitative imaging biomarkers for Yttrium-90 distribution on Bremsstrahlung single photon emission computed tomography after resin-based radioembolization. J Nucl Med 69(1): 182–236
Smits ML, Prince JF, Rosenbaum CE, van den Hoven AF, Nijsen JF, Zonnenberg BA, Seinstra BA, Lam MG, van den Bosch MA (2013) Intra-arterial radioembolization of breast cancer liver metastases: a structured review. Eur J Pharmacol 69(1):182–236
Soydal C, Kucuk ON, Bilgic S, Ibis E (2016) Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med 30:29–34
PubMedCrossRefTomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, Farsad K (2018) Long-term toxicity after transarterial radioembolization with Yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 29:858–865
PubMedCrossRefVenkatanarasimha N, Gogna A, Tong KTA, Damodharan K, Chow PKH, Lo RHG, Chandramohan S (2017) Radioembolisation of hepatocellular carcinoma: a primer. Clin Radiol 72:1002–1013
PubMedCrossRefVilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aube C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, Sarah Trial Group (2017) Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 18:1624–1636
PubMedCrossRefWasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A, van Hazel G, Sharma RA (2017) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 18:1159–1171
PubMedPubMedCentralCrossRefXing M, Lahti S, Kokabi N, Schuster DM, Camacho JC, Kim HS (2016) 90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival. Clin Nucl Med 41:21–27
PubMedCrossRefYoo HS, Lee JT, Kim KW, Kim BS, Choi HJ, Lee KS, Park CI, Park CY, Suh JH, Loh JJ (1991) Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 68:1878–1884
PubMedCrossRef